Our Approach To Investing

This is an incredibly promising time for the Type 1 diabetes (T1D) space, with multiple avenues for therapeutic intervention and cures based on natural history of the disease and the latest research. We are modality agnostic, investing across a spectrum of differentiated T1D approaches with potential to accelerate prevention, treatments, and cures.

Impact Investing

As an impact investment fund, we exclusively make equity investments with the same level of evaluation and investment execution approach as a traditional VC fund. We typically syndicate with experienced biotech investors and conduct diligence leveraging our extensive expertise in the space. All private capital raised to be deployed by the T1D Fund is recorded as a charitable donation and receives associated tax benefits at time of contribution.

As we grow our portfolio, we seek differentiated, disease-modifying therapeutics and treatments with curative potential for T1D, from disease prevention to reversal, with additional interest in metabolic control and areas of high unmet need.

Geographically, our investments have spanned the globe—we believe innovation has no bounds.

Other Investment Considerations

Process

All investments are reviewed on a continuous basis, as the T1D Fund team evaluates whether each opportunity aligns with the T1D Fund’s overall strategy and mission. Post investment, we remain actively involved with our companies by taking governance roles and leveraging relationships to provide strategic input and connect them with a broad network of experts and advocacy groups.

Diligence

Our team, alongside Breakthrough T1D (formerly JDRF), leverages its expertise to assess each investment opportunity and work with each company to fully understand the value proposition as well as impact.

Technology

We believe there are multiple avenues toward curative treatments for T1D and are willing to explore many different types of modalities and approaches.

R&D

We’re stage agnostic and invest in discovery through clinical stage assets; however, we prefer finding conviction around a clear product thesis that is backed by early validation.

Financing Structure

We consider traditional and novel investment structures in both private and publicly traded companies.

If you’d like to know more about our investing guidelines or want to talk to us about contributing, you can contact us here.

Supporting The Next Generation Of T1D Treatments

The T1D Fund is Uniquely Positioned to Transform the Therapeutic Landscape of T1D Through our Investment Approach.

The T1D Fund strongly supports companies that are pursuing development of curative treatments to accelerate life-changing solutions to cure, prevent, and treat T1D.

We invest in opportunities that can mitigate developmental risk while generating returns. These returns on investments are important to continue to fund investments that would support the next generation of life-changing T1D treatments. Our recognition as an impact investor and champion for treatments within the space has allowed us to attract and collaborate with well-known investors to create compelling syndicates necessary to finance T1D opportunities.

As an impact investment fund, neither management nor donors to the T1D Fund receive distributions. Our returns are reinvested back into the Fund so that we can support the next generation of life-changing T1D treatments.